Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend - Gilead Sciences (NASDAQ:GILD)

Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend - Gilead Sciences (NASDAQ:GILD)

Gilead Sciences Inc. (NASDAQ:GILD) announced on Friday data from the Phase 3 ASCENT-07 study of Trodelvy (sacituzumab govitecan-hziy) versus chemotherapy in HR+/HER2-negative metastatic breast cancer patients. The trial included patients who received prior endocrine therapy and were candidates for cytotoxic chemotherapy. The study did not meet the primary endpoint of progression-free survival (PFS), the time during and after treatment when a dis…

Gilead Trodelvy trial fails in breast cancer (GILD:NASDAQ)

Gilead Sciences (GILD) stock is in focus as the company fails in a late-stage trial which tested its Trodelvy cancer drug as a first-line therapy for breast cancer. Read more here.

Gilead’s breast cancer drug fails to meet main goal of late-stage study

(Reuters) -Gilead Sciences said on Friday its breast cancer drug Trodelvy did not significantly lower the risk of disease progression in patients when used as a first-line treatment, failing to meet the main goal of a late-stage study. Gilead said an early trend for extending overall survival, a key measure of treatment efficacy, was observed favoring patients treated with Trodelvy, compared to chemotherapy. The data for overall survival, howeve…

Why one expert thinks Gilead can produce a $25 HIV prevention shot, help eradicate the disease in the U.S.

For the past few months, CVS Caremark has declined to add a groundbreaking HIV prevention drug from Gilead Sciences to its formularies. Clinical trials showed the twice-a-year injectable, called Yeztugo, was highly effective in preventing the infectious disease, prompting enthusiasm about combating HIV globally. But the pharmacy benefits manager has argued that the $28,000 price tag — before any rebates or discounts — in the U.S. is too high. Ju…

Gilead’s Trodelvy fails Phase 3 breast cancer study

Gilead’s Trodelvy failed to meet the primary endpoint in a Phase 3 trial for certain breast cancer patients, marking another setback for a key drug in Gilead’s cancer portfolio. Trodelvy has faced a series of ...

Trodelvy Misses Primary Endpoint in ASCENT-07 Breast Cancer Trial

In the ASCENT-07 trial, Trodelvy after endocrine therapy did not improve progression-free survival vs chemotherapy in HR+/HER2- metastatic breast cancer.